Literature DB >> 18854190

Engineering higher affinity T cell receptors using a T cell display system.

Adam S Chervin1, David H Aggen, John M Raseman, David M Kranz.   

Abstract

The T cell receptor (TCR) determines the cellular response to antigens, which are presented on the surface of target cells in the form of a peptide bound to a product of the major histocompatibility complex (pepMHC). The response of the T cell depends on the affinity of the TCR for the pepMHC, yet many TCRs have been shown to be of low affinity, and some naturally occurring T cell responses are poor due to low affinities. Accordingly, engineering the TCR for increased affinity for pepMHC, particularly tumor-associated antigens, has become an increasingly desirable goal, especially with the advent of adoptive T cell therapies. For largely technical reasons, to date there have been only a handful of TCRs engineered in vitro for higher affinity using well established methods of protein engineering. Here we report the use of a T cell display system, using a retroviral vector, for generating a high-affinity TCR from the mouse T cell clone 2C. The method relies on the display of the TCR, in its normal, signaling competent state, as a CD3 complex on the T cell surface. A library in the CDR3alpha of the 2C TCR was generated in the MSCV retroviral vector and transduced into a TCR-negative hybridoma. Selection of a high-affinity, CD8-independent TCR was accomplished after only two rounds of flow cytometric sorting using the pepMHC SIYRYYGL/Kb (SIY/Kb). The selected TCR contained a sequence motif in the CDR3alpha with characteristics of several other TCRs previously selected by yeast display. In addition, it was possible to directly use the selected T cell hybridoma in functional assays without the need for sub-cloning, revealing that the selected TCR was capable of mediating CD8-independent activity. The method may be useful in the direct isolation and characterization of TCRs that could be used in therapies with adoptive transferred T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854190      PMCID: PMC2680719          DOI: 10.1016/j.jim.2008.09.016

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  58 in total

1.  The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules.

Authors:  A M Wegener; F Letourneur; A Hoeveler; T Brocker; F Luton; B Malissen
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

2.  Derivation of a T cell hybridoma variant deprived of functional T cell receptor alpha and beta chain transcripts reveals a nonfunctional alpha-mRNA of BW5147 origin.

Authors:  F Letourneur; B Malissen
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

3.  T cell tolerance by clonal elimination in the thymus.

Authors:  J W Kappler; N Roehm; P Marrack
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

4.  Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status.

Authors:  J Gorski; M Yassai; X Zhu; B Kissela; B ] Kissella B [corrected to Kissela; C Keever; N Flomenberg
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

5.  Retroviral vectors displaying functional antibody fragments.

Authors:  S J Russell; R E Hawkins; G Winter
Journal:  Nucleic Acids Res       Date:  1993-03-11       Impact factor: 16.971

6.  Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness.

Authors:  K Matsui; J J Boniface; P Steffner; P A Reay; M M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes.

Authors:  Y Sykulev; A Brunmark; M Jackson; R J Cohen; P A Peterson; H N Eisen
Journal:  Immunity       Date:  1994-04       Impact factor: 31.745

8.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

9.  TCR alpha-CD3 delta epsilon association is the initial step in alpha beta dimer formation in murine T cells and is limiting in immature CD4+ CD8+ thymocytes.

Authors:  K P Kearse; J L Roberts; A Singer
Journal:  Immunity       Date:  1995-04       Impact factor: 31.745

10.  Distinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation.

Authors:  Lindsay L Jones; Leremy A Colf; Jennifer D Stone; K Christopher Garcia; David M Kranz
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

View more
  38 in total

Review 1.  T cell engineering as therapy for cancer and HIV: our synthetic future.

Authors:  Carl H June; Bruce L Levine
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

2.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

3.  Weaponizing T-cell receptors through molecular engineering.

Authors:  Elissa K Leonard; Michael I Leff; Jamie B Spangler
Journal:  J Biol Chem       Date:  2019-04-12       Impact factor: 5.157

4.  Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex.

Authors:  Daniel T Harris; Ningyan Wang; Timothy P Riley; Scott D Anderson; Nishant K Singh; Erik Procko; Brian M Baker; David M Kranz
Journal:  J Biol Chem       Date:  2016-09-28       Impact factor: 5.157

Review 5.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

Review 6.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity.

Authors:  Preeti Sharma; Daniel T Harris; Jennifer D Stone; David M Kranz
Journal:  Cancer Immunol Res       Date:  2019-09-23       Impact factor: 11.151

9.  Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.

Authors:  Thomas M Schmitt; David H Aggen; Ingunn M Stromnes; Michelle L Dossett; Sarah A Richman; David M Kranz; Philip D Greenberg
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

10.  Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides.

Authors:  Natalie A Bowerman; Leremy A Colf; K Christopher Garcia; David M Kranz
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.